Isatuximab (ISA) är en monoklonal antikropp riktad mot CD38-receptorn som visat lovande resultat och godtagbar toleransprofil i fas 1/2-studier av patienter med recidiverande/refraktärt multipelt myelom (RRMM). I januari 2017 rekryterades den första patienten till en öppen, prospektiv, randomiserad fas 3-studie av multicentertyp med målet att rekrytera cirka 300 vuxna patienter (150 i varje arm). Kriterier för deltagande i studien är minst två tidigare behandlingslinjer med lenalidomid eller en proteasomhämmare eller dessa i kombination. Syftet med fas 3-studien är att utvärdera behandlingsnytta och säkerhet med ISA i kombination med pomalidomid och dexametason och jämföra det med behandling med enbart pomalidomid och dexametason. Primärt resultatmått är progressionsfri överlevnad, det vill säga tid från randomisering till sjukdomsprogress eller död av alla orsaker. Övriga resultatmått är bland annat svarsfrekvens och total överlevnad. Behandlingen ges i cykler om 28 dagar och patienterna fortsätter med behandlingen fram tills att sjukdomen progredierar, oacceptabla biverkningar uppkommer eller de…

Click and hear Paul G. Richardson present the data for the combination therapy with elotuzumab in combination pomalidomide and dexamethasone for relapsed/refractory multiple myeloma. Elotuzumab, an immunostimulatory monoclonal antibody targeting SLAMF7, enables selective killing of MM cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide. This study demonstrated sustained and clinically relevant PFS and OS benefits for elotuzumab plus pomalidomide and dexamethasone vs pomalidomide in combination with dexamethasone, with no new safety signals. These data support the long-term favorable efficacy–safety profile of elotuzumab plus pomalidomide and dexamethasone and suggest this regimen could be considered as a standard of care for patients with relapsed/refractory multiple myeloma after failure of lenalidomide and a proteasome inhibitor.

Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma. In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + low-dose dexamethasone in patients refractory to pomalidomide and/or daratumumab (HORIZON-study).

MEST SETE MEDtalks

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer   Se hele webinar

ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

<script src="https://fast.wistia.com/embed/medias/4rwno0og6n.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_4rwno0og6n videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/4rwno0og6n/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/asco-2019-breakthrough-for-cdk4-6-inhibitor-endocrine-therapy-in-premenopausal-patients-with-hr-her2%e2%88%92-advanced-breast-cancer/'>Se hele webinar
ASCO 2019: Breakthrough for CDK4/6 inhibitor + endocrine therapy in premenopausal patients with HR+/HER2− advanced breast cancer

ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

<script src="https://fast.wistia.com/embed/medias/rp2kqsxgnz.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_rp2kqsxgnz videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/rp2kqsxgnz/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/asco-2019-updated-overall-survival-for-treatment-of-locally-advanced-or-metastatic-triple-negative-breast-cancer/'>Se hele webinar
ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/eha-2019-venetoclax-plus-obinutuzumab-improves-pfs-and-mrd-negativity-in-patients-with-previously-untreated-cll-and-comorbidities/'>Se hele webinar
EHA 2019: Venetoclax plus obinutuzumab improves PFS and MRD negativity in patients with previously untreated CLL and comorbidities

EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

<script src="https://fast.wistia.com/embed/medias/abbfjgn32v.jsonp" async></script><script src="https://fast.wistia.com/assets/external/E-v1.js" async></script><div class="wistia_responsive_padding" style="padding:56.25% 0 0 0;position:relative;"><div class="wistia_responsive_wrapper" style="height:100%;left:0;position:absolute;top:0;width:100%;"><div class="wistia_embed wistia_async_abbfjgn32v videoFoam=true" style="height:100%;position:relative;width:100%"><div class="wistia_swatch" style="height:100%;left:0;opacity:0;overflow:hidden;position:absolute;top:0;transition:opacity 200ms;width:100%;"><img src="https://fast.wistia.com/embed/medias/abbfjgn32v/swatch" style="filter:blur(5px);height:100%;object-fit:contain;width:100%;" alt="" onload="this.parentNode.style.opacity=1;" /></div></div></div></div>
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patientsEHA 2019: Highly effective combination for initial therapy for young, fit CLL patients&nbsp;&nbsp;&nbsp;<a href='https://bestprac.se/webinar/eha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patientseha-2019-highly-effective-combination-for-initial-therapy-for-young-fit-cll-patients/'>Se hele webinar
EHA 2019: Highly effective combination for initial therapy for young, fit CLL patients

The SAM domain and HD domain 1 (SAMHD1) protein is a deoxynucleoside triphosphate (dNTP) triphosphohydrolase, which has been initially described to restrict human immunodeficiency virus type 1 (HIV-1) in the immune cells. This study shows that SAMHD1 is expressed in approximately half of de novo diffuse large B-cell Lymphomas at a variable level and correlates with cell of origin (GC), biomarkers of tumor aggressiveness (eg MYC, proliferation) and clinical outcome.

In this MEDtalk Stine Mikkelsen present the first study investigating submicroscopic copy number variations/ uniparental disomy in idiopathic cytopenia of undetermined significance patients. In a subset of patients with otherwise no detectable genetic abnormalities, Stine Mikkelsen and colleagues identified structural variations involving genes recurrently affected in MDS. Their results suggest that SNP-A can aid the prognostics of ICUS patients by identifying submicroscopic structural variations as risk markers for poor OS.

TOURMALINE-MM3 is a phase 3, double-blind, placebo-controlled study, where ixazomibimproved PFS, and is the first study to evaluate the impact ofmaintenance therapyon quality of life in postautologous stem cell transplant in newly diagnosed multiple myeloma. In this MEDtalkFredrik Schjesvoldpresent the data from the study showing, that active treatment with ixazomibdid not have an adverse impact on HRQoL.

#Senaste Tidskrifter

Onkologi / Hematologi

NR. 4 • september 2018
Årgång 2
  • EHA 2018
  • Prostatacancer
  • Bröstcancerrisk

EHA 2019

ASCO 2019

ASH 2018

#

Onkologi / Hematologi

Vladimir Lazarevic,

Vladimir Lazarevic,
överläkare

Hareth Nahi

Hareth Nahi
med.dr, fil.dr